Fig. 2.

Characterization of CM@CaPyro NGs. (A) TEM analysis of CM@CaPyro vaccine. (B) Zeta potential of CaPyro NGs and CM@CaPyro NGs measured by DLS. (C) Stability of CM@CaPyro NGs dispersed in PBS (n = 3; mean ± SEM). (D) Cell viability of CM@CaPyro NGs on DC 2.4 cells. (E) SDS-PAGE protein tracking was performed on B16-OVA whole cell lysate, B16-OVA cell membranes, CM@CaPyro NGs and CaPyro NGs, and the protein bands were stained with Coomassie blue. (F) Western blotting detection of tumor-associated antigen (gp100), self-antigen (Trp-2), chaperone protein (calreticulin) on whole B16-OVA cell lysate, B16-OVA cell membranes, CM@CaPyro NGs and CaPyro NGs.